camelid antibody fragment inhibits formation amyloid fibrils human lysozyme
amyloid diseases characterized aberrant assembly specific protein protein fragment fibrils plaques deposited various organs tissues- often serious pathological consequences non-neuropathic systemic amyloidosis - associated single point mutations gene coding human lysozyme report single-domain fragment camelid antibody- raised wild-type human lysozyme inhibits vitro aggregation amyloidogenic variant d67h structural studies reveal epitope includes neither site mutation residues region protein structure destabilized mutation instead binding antibody fragment achieves effect restoring structural cooperativity characteristic wild-type protein appears occur least part transmission long-range conformational effects interface two structural domains protein thus reducing ability amyloidogenic protein form partly unfolded species can effective method preventing aggregation suggesting approaches rational design therapeutic agents directed protein deposition diseases
